Drug Transporter (DT) Information

General Information of DT
DT ID DTD0257
Gene Name SLC2A2
Protein Name Glucose transporter type 2, liver
Gene ID
6514
UniProt ID
P11168
TCDB ID
2.A.1.1.29
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 5C65_A; 5EQG_A

Identity: 50.392% ; 53.053%

Minimized Score: -1347.614 kcal/mol

Detail: Structure Info

Synonyms Solute carrier family 2, facilitated glucose transporter member 2; GLUT-2; SLC2A2; GLUT2
DT Family Major Facilitator Superfamily (MFS)
Sugar Porter (SP) Family
Tissue Specificity Liver, insulin-producing beta cell, small intestine and kidney.
Function This transporter as a facilitative glucose transportermay participate with the Na+/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell.
Endogenous Substrate(s) Glucose
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
2-Deoxyglucose
 Phase 1/2 Drug Info Cancer 2A00-2F9Z [1]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
3,5-diiodo-l-thyronine
92859
EM Info Identified using diet-induced obese mice [2]

Drug-DT Affinity Assessed by Cell Line

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
2-Deoxyglucose Phase 1/2 Drug Info Human pancreatic beta cells-GLUT2 Km = 1120 microM [1]
References
1 GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab. 2011 Dec;104(4):648-53.
2 3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism. Front Endocrinol (Lausanne). 2018 Jul 25;9:427.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.